Nexgel

Nexgel EBITDA per Employee

The EBITDA per Employee of Nexgel (NXGL) as of Nov 3, 2026 is -335,200.00 USD. In the previous year, EBITDA per Employee was -339,800.00 USD — a change of -1.35% (higher).

EBITDA per Employee

-335,200.00USD

YoY

-1.35%

Last updated:

EBITDA per Employee of Nexgel is 2025 -335,200.00 USD. EBITDA per Employee of Nexgel was 2024 -339,800.00 USD. It decreases by -1.35% higher compared to the previous year.

The Nexgel EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-185,800.00 USD
Jan 1, 2019
-190,400.00 USD
Jan 1, 2020
-224,400.00 USD
Jan 1, 2021
-230,200.00 USD
Jan 1, 2022
-339,000.00 USD
Jan 1, 2023
-335,100.00 USD
Jan 1, 2024
-339,800.00 USD
Jan 1, 2025
-335,200.00 USD
The Nexgel EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-335,200.00USD-1.35%
-339,800.00USD+1.40%
-335,100.00USD-1.15%
-339,000.00USD+47.26%
-230,200.00USD+2.58%
-224,400.00USD+17.86%
-190,400.00USD+2.48%
-185,800.00USD+91.74%
-96,900.00USD-48.02%
-186,400.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nexgel Stock analysis

What does Nexgel do? NexGel Inc. generates revenue through the sale of proprietary aqueous polymer hydrogels manufactured using electron beam cross-linking technology. The company markets MedaGel for over-the-counter wound care products like blister and pain remedies, and LumaGel Beauty for cosmetic applications including wrinkle and skin creams. Its customers, primarily healthcare providers and cosmetic brands, purchase these branded gels for integration into their own product lines. NexGel's manufacturing focuses on high water content hydrogels tailored to medical and beauty segments through custom formulations based on its proprietary technologies. The firm's MedaGel brand targets the OTC medical segment with solutions for wound care and pain relief, while LumaGel Beauty serves the cosmetics market with skincare products. Both brands leverage NexGel's proprietary mixing, coating, and crosslinking technologies to produce gels sold to customers who then market them under their own labels. The company's revenue streams derive from direct sales of these branded gels to manufacturers who incorporate them into final consumer products for the U.S. and international markets. NexGel's product portfolio centers on hydrogels for wound care, diagnostics, drug delivery, and cosmetics, with MedaGel and LumaGel Beauty representing its two primary brand segments. The company's manufacturing expertise in custom gels allows it to serve both medical and beauty industries through its branded product lines. Revenue is generated through the sale of these branded gels to customers who then distribute them as part of their own branded offerings in the U.S. and global markets. Nexgel is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nexgel stock

EBITDA per Employee of Nexgel is -335,200.00 USD in 2025.

EBITDA per Employee of Nexgel changed from -339,800.00 USD to -335,200.00 USD, representing a -1.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Nexgel since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Nexgel historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Nexgel

All Key Metrics — Nexgel